Table 3.
Ongoing clinical trials with Pembrolizumab in multiple myeloma including smoldering multiple myeloma.
| Title | N | Con. | Experimental arm | Identifier Phase |
|---|---|---|---|---|
| Pembrolizumab for Smoldering Multiple Myeloma (SMM) | 16 | SMM | Pembrolizumab |
NCT02603887 1 |
| NY-ESO-1c259T Alone and in Combination With Pembrolizumab for Multiple Myeloma | 20 | RRMM | a) NY-ESO-1c259T cells/Pembrolizumab b) NY-ESO-1c259T cells |
NCT03168438 1 |
| A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023) | 84 | RRMM | a) Pembrolizumab/Lenalidomide/Dexamethasone b) Pembrolizumab/Carfilzomib/Dexamethasone |
NCT02036502 1 |
| Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma | 24 | RRMM | Pembrolizumab/RT |
NCT03267888 1 |
| ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (KEYNOTE145) | 159 | RRMM | Pembrolizumab/Acalabrutinib |
NCT02362035 1, 2 |
| Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668) | 57 | RRMM | Pembrolizumab/Daratumumab |
NCT03221634 2 |
| Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Participants With Relapsed Multiple Myeloma | 42 | RRMM | Pembrolizumab/Ixazomib/Dexamethasone |
NCT03506360 2 |
N - estimated enrolment; Con. - condition; RRMM - relapsed or refractory multiple myeloma; SMM - smoldering myeloma; Pembrolizumab - mAb anti-PD-1; Acalabrutinib - Bruton's tyrosine kinase inhibitor; NY-ESO-1c259T cells - autologous genetically modified T Cells.